（文章来源：证券日报） 证券日报网讯 2月26日，舒泰神在互动平台回答投资者提问时表示，公司正按照发补通知要求组织相关 部门落实并尽快补充提交相关材料，继续推进注射用STSP-0601附条件批准上市工作。 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology sector is "Outperform the Market" (maintained) [2] Core Insights - The pharmaceutical sector underperformed the market in Q4 2025, with the overall sector down by 9.3% compared to a slight decline of 0.2% in the CSI 300 index. Notably, the pharmaceutical commercial segment showed a positive performance with a 5.3% increase, while other segments like medical services and biological products experienced significant declines [4][8] - The total net asset value of pharmaceutical funds decreased to 358.4 billion yuan, a 9.0% decline quarter-on-quarter. This marks the first time since 2019 that passive pharmaceutical funds (181.8 billion yuan) surpassed active funds (176.5 billion yuan) [4][14] - The overall pharmaceutical holdings across all funds dropped to 7.97%, a decrease of 1.71 percentage points. Active pharmaceutical funds maintained a high concentration with a holding ratio of 97.45% [23] Summary by Sections 1. Market Review - In Q4 2025, the pharmaceutical and biotechnology sector lagged behind the CSI 300 index, with a decline of 9.3%. The chemical pharmaceuticals segment fell by 9.6%, biological products by 12.4%, and medical devices by 10.6% [8] 2. Pharmaceutical Fund Size - As of Q4 2025, the net asset value of pharmaceutical funds was 358.4 billion yuan, down 9.0% from the previous quarter. Active funds accounted for 176.5 billion yuan, a 14.6% decrease, while passive funds reached 181.8 billion yuan, down 2.8% [14] 3. Pharmaceutical Holdings Ratio - The pharmaceutical holdings ratio for all funds was 7.97%, down 1.71 percentage points. Active pharmaceutical funds had a holding ratio of 97.08%, while passive funds had 97.83% [23] 4. Holdings Structure Analysis - The highest sub-sector holding in Q4 2025 was chemical preparations at 37.5%, followed by other biological products at 20.8%. The largest increases in holdings were seen in traditional Chinese medicine (+0.98 percentage points) and chemical preparations (+0.62 percentage points) [29] 5. Additions and Reductions in Holdings - The top three pharmaceutical stocks by the number of funds holding them were Heng Rui Medicine (498 funds), WuXi AppTec (408 funds), and Mindray Medical (204 funds). Notably, Heng Rui Medicine saw a reduction of 236 funds, while Ying En Biological-B experienced an increase of 47 funds [84][88]

Policy Developments - The National Health Commission and 10 other departments jointly issued the "National Basic Drug Directory Management Measures," which revises six key areas, including legal policy basis, directory structure optimization, management mechanism improvement, emphasis on clinical value, dynamic adjustment mechanism, and monitoring and evaluation enhancement [1][2]. Drug and Device Approvals - Hengrui Medicine announced that its injection of Rukang Qutuzumab has been included in the list of breakthrough therapy varieties, marking the 10th indication for this drug, aimed at treating locally advanced or metastatic non-small cell lung cancer patients with HER2 mutations [3]. - Shanghai Pharmaceuticals received approval for the listing application of the raw material drug Tamsulosin Hydrochloride, which is used for treating benign prostatic hyperplasia, with an investment of approximately RMB 1.5 million in its development [4]. Financial Reports - WuXi Biologics expects a 46.3% year-on-year increase in net profit for the full year 2025, projecting revenues of approximately RMB 21.79 billion and an adjusted net profit of about RMB 6.59 billion [5]. - Eucare Pharmaceuticals reported a 48.21% decline in net profit for 2025, with revenues of RMB 334 million, reflecting a 7.73% increase [6]. Capital Markets - Watson Bio plans to invest RMB 450 million to establish a biological industry investment fund with a target size of RMB 1 billion, focusing on synthetic biology and related sectors [7]. - Hite Bio intends to acquire a 23.08% stake in Beijing Shadong for RMB 62.02 million, increasing its ownership to 98.84% [8]. - Duorui Pharmaceuticals announced a partial tender offer to acquire 24.30% of its shares at a price of RMB 32.07 per share [9]. Industry Events - China's first C909 "airplane hospital" successfully completed its first in-flight surgery in Laos, providing medical services to over 600 patients since its launch [10]. - Researchers revealed the key mechanism of the "weight loss miracle drug" Semaglutide, showing its significant cartilage protection effects independent of weight loss, providing new drug development targets for metabolic osteoarthritis [11]. Public Sentiment Alerts - Shuyou Shen announced that its major shareholder, Xiangtang Group, has cumulatively reduced its holdings by 4.78 million shares, accounting for 1% of the total share capital [12].

（文章来源：证券日报） 证券日报网讯 2月11日，舒泰神发布公告称，公司原持股5%以上股东香塘集团通过大宗交易于2025年 12月12日至2026年2月10日合计减持477.77万股，占总股本1%，减持计划已实施完毕，香塘集团及其一 致行动人合计持股比例降至4.69%。 ...

证券代码：300204 证券简称：舒泰神 公告编号：2026-003 舒泰神（北京）生物制药股份有限公司 舒泰神（北京）生物制药股份有限公司（以下简称"公司"或"舒泰神"） 于 2025 年 11 月 05 日披露了《关于持股 5%以上股东减持股份的预披露公告》（公 告编号 2025-076），香塘集团有限公司（以下简称"香塘集团"）计划在本减持计 划公告披露之日起 15 个交易日后的 3 个月内，即 2025 年 11 月 27 日至 2026 年 02 月 26 日期间（法律法规规定的窗口期不减持），通过证券交易所以大宗交易 方式减持股份合计不超过 477.77 万股，占公司有表决权总股本的 1%。若计划减 持期间公司有送股、配股、资本公积金转增股本等股份变动事项，则对上述股份 减持数量进行相应调整。 2025 年 12 月 29 日，公司披露了《关于持股 5%以上股东及其一致行动人减 持至 5%以下暨权益变动的提示性公告》（公告编号：2025-085）。 近日，公司收到香塘集团的告知函，香塘集团本次减持计划实施完毕。根据 《上市公司股东减持股份管理暂行办法》、《深圳证券交易所上市公司自律监管指 引第 1 ...

持股5%以上股东香塘集团于2025年11月至12月连续减持，包括2025年12月26日减持后持股比例降至5% 以下。该股东在两个月内发起多轮减持，市场担忧其可能进一步影响股价稳定性和公司治理信心。 产品研发进展 经济观察网根据公开信息，舒泰神（300204）在2026年初有以下值得关注的事件动态，主要涉及资本运 作、业绩表现、研发进展和股东行为等方面。这些事件基于公司公告和媒体报道整理，具体时间节点和 细节请以官方披露为准。 定增股票 舒泰神于2025年10月披露新一轮定增方案，计划募资不超过12.53亿元(其中8.83亿元用于创新药物研 发，3.7亿元补充流动资金)，该方案已获深交所受理。这是公司自2020年以来第四次推出定增，前三次 均终止，本次规模为上市以来最大，其审批结果可能对公司研发资金链产生重要影响。 业绩经营情况 2026年1月28日，公司发布2025年业绩预告，预计归属于上市公司股东的净利润为-8,532.76万元 至-6,981.35万元，亏损主要受核心产品舒泰清收入下降拖累，而苏肽生销量略有增长。正式年报预计在 2026年4月前披露，需关注实际亏损幅度及现金流改善情况。 股东减持 2025 ...

Core Viewpoint - The Biotech Index (970038) closed at 2196.51 points, up 0.05%, with a trading volume of 15.75 billion yuan and a turnover rate of 1.32% [1] Group 1: Index Performance - On the day, 20 stocks in the Biotech Index rose, with Furuimei leading at a 4.45% increase, while 28 stocks fell, with Aimeike leading the decline at 2.87% [1] - The net outflow of main funds from the Biotech Index constituents totaled 327 million yuan, while retail funds saw a net inflow of 162 million yuan [1] Group 2: Top Constituents - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 13.73%, latest price of 190.36 yuan, and a market cap of 230.8 billion yuan [1] - Deep Technology (sz000021) with a weight of 5.05%, latest price of 28.69 yuan, and a market cap of 45.09 billion yuan [1] - Tigermed (sz300347) with a weight of 4.85%, latest price of 66.60 yuan, and a market cap of 57.34 billion yuan [1] - Other notable constituents include Changchun High-tech, Kanglong Chemical, and Yuyue Medical, all within the biotech sector [1] Group 3: Fund Flow Details - Detailed fund flow for selected stocks shows: - Kanglong Chemical (300759) had a main fund inflow of 10.6 million yuan, but retail funds saw a net outflow of 87.37 million yuan [2] - Furuimei (300049) experienced a main fund inflow of 63.48 million yuan, while retail funds had a net outflow of 64.28 million yuan [2] - Mindray Medical (300760) had a main fund inflow of 45.80 million yuan, with retail funds also experiencing a net outflow [2]

证券日报网讯2月10日，舒泰神（300204）在互动平台回答投资者提问时表示，公司2025年度向特定对 象发行股票事项正在有序推进中，发行定价基准日及发行价格都尚未确定。 ...

Group 1 - The core index of the biotechnology sector, the Biotechnology Index (970038), closed at 2195.46 points, reflecting an increase of 0.82% with a trading volume of 16.95 billion yuan and a turnover rate of 1.47% [1] - Among the constituent stocks of the Biotechnology Index, 39 stocks experienced an increase, with Deep Technology leading the gain at 6.07%, while 10 stocks saw a decline, with Shuotai Shen leading the drop at 2.66% [1] Group 2 - The net inflow of main funds into the Biotechnology Index's constituent stocks totaled 80.71 million yuan, while the net outflow from speculative funds was 48.99 million yuan, and the net outflow from retail investors was 31.72 million yuan [2] - Detailed fund flow information for the constituent stocks is available in the accompanying table [2]

证券日报网讯 2月9日，舒泰神在互动平台回答投资者提问时表示，公司高度重视与投资者的交流，并 严格遵守信息披露相关规定，确保披露的信息真实、准确、完整。基于法规的要求，公司在互动平台上 回复时，需以已公开披露的信息为依据，避免发布未公开的重大信息，亦不得使用可能误导投资者的表 述。因此，对于已在公告或公开信息中披露的内容，公司会尽力协助说明；对于尚未达到披露标准或仍 在推进中的事项，公司将根据进展情况，依法依规及时履行信息披露义务。公司将持续通过法定渠道及 时传递公司动态。 （编辑 袁冠琳） ...